Copyright © 2002 by the European Society of Cardiology.
Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE
a Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, U.S.A.
b Hahnemann University Hospital, Philadelphia, U.S.A.
d Harvard Clinical Research Institute, Boston, U.S.A.
c Canadian Heart Research Centre, Department of Medicine, University of Toronto, Toronto, Canada
revised April 21, 2001; accepted April 25, 2001
Abstract
Background Enoxaparin treatment is associated with a 20% reduction in clinical events during the acute phase of management of patients with unstable angina/non ST elevation myocardial infarction. Interest in the use of enoxaparin would be enhanced further if evidence of a durable treatment benefit over the long term could be provided.
Methods Event rates at 1 year for the composite end-point of death/non-fatal myocardial infarction/urgent revascularization and its individual components were ascertained from the TIMI 11B and ESSENCE databases.
Results There was no evidence of heterogeneity between TIMI 11B and ESSENCE in tests for interactions between treatment and trial. A significant treatment benefit of enoxaparin on the rate of death/non-fatal myocardial infarction/urgent revascularization was observed at 1 year (hazard ratio 0·88; P=0·008). The event rate was 25·8% in the unfractionated heparin group and 23·3% in the enoxaparin group, an absolute difference of 2·5%. A progressively greater treatment benefit of enoxaparin was observed as the level of patient risk at baseline increased. Treatment effects for the individual end-point elements ranged from 9–14%, favouring enoxaparin.
Conclusions The stable absolute difference in event rates of 2·5% seen at 8 days and again at 1 year favouring enoxaparin may be due to more effective control of the thrombotic process surrounding the index event. Once the pharmacological effect of enoxaparin had dissipated there was no rebound increase in events. Thus, those patients who had received enoxaparin acutely were protected from experiencing a deterioration of the original therapeutic benefit. These findings regarding enoxaparin add to the data to be considered by clinicians when selecting an antithrombin for the acute phase of management of unstable angina/non-ST elevation myocardial infarction.
Key Words: Enoxaparin, low molecular weight heparin, meta-analysis, antithrombin
f1 Correspondence: Elliott M. Antman, M.D., Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, U.S.A.
References
- Barrowcliffe T, Johnson E, Thomas D. Low molecular weight heparin. Chicester: John Wiley & Sons; 1992. p. 209
- Bounameaux H. Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic disease. New York: Marcel Dekker, Inc; 1994. p. 323
- Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688–698
[Free Full Text] - Antman EM, Cohen M, Radley D. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation. 1999;100:1602–1608
[Abstract/Free Full Text] - Goodman SG, Cohen M, Bigonzi F. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: 1-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol. 2000;36:693–698
[Abstract/Free Full Text] - Antman EM, Cohen M, Bernink PJLM. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. J Am Med Assoc. 2000;284:835–842
[Abstract/Free Full Text] - Antman EM, McCabe CH, Gurfinkel EP. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100:1593–1601
[Abstract/Free Full Text] - Cohen M, Demers C, Gurfinkel EP. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447–452
[Abstract/Free Full Text] - Bozovich GE, Gurfinkel EP, Antman EM. Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time. Am Heart J. 2000;140:637–642[CrossRef][Web of Science][Medline]
- Antman EM. Enoxaparin: a new standard of care. Eur Heart J. 2000;2:F7–F11
- Morrow DA, Antman EM, Tanasijevic M. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol. 2000;36:1812–1817
[Abstract/Free Full Text] - Goodman SG, Barr A, Sobtchouk A. Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy. J Am Coll Cardiol. 2000;36:1507–1513
[Abstract/Free Full Text] - Mark DB, Cowper PA, Berkowitz SD. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Circulation. 1998;97:1702–1707
[Abstract/Free Full Text] - O'Brien BJ, Willan A, Blackhouse G. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? Am Heart J. 2000;139:423–429[Web of Science][Medline]
- Theroux P, Waters D, Lam J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 1992;327:141–145[Abstract]
- Mombelli G, Marchetti O, Haeberli A. Effect of intravenous heparin infusion on thrombin-antithrombin complex and fibrinopeptide A in unstable angina. Am Heart J. 1998;136:1106–1113[CrossRef][Web of Science][Medline]
- Lane DA, Denton J, Flynn AM. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J. 1984;218:725–732[Web of Science][Medline]
- Abildgaard U, Lindahl AK, Sandset PM. Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. Haemostasis. 1991;21:254–257[Web of Science][Medline]
- Hoppensteadt DA, Jeske W, Fareed J. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinolysis. 1995;6:S57–64
- Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97:251–256
[Abstract/Free Full Text] - Montalescot G, Philippe F, Ankri A. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation. 1998;98:294–299
[Abstract/Free Full Text] - Antman EM, Handin R. Low-molecular-weight heparins: an intriguing new twist with profound implications. Circulation. 1998;98:287–289
[Free Full Text] - Brieger D, Dawes J. Long-term persistence of biological activity following administration of Enoxaparin sodium (clexane) is due to sequestration of antithrombin-binding low molecular weight fragments—comparison with unfractionated heparin. Thromb Haemost. 1996;75:740–746[Web of Science][Medline]
- Lindhout, T, Hemker, H, Anticoagulant mechanism of action of low molecular weight heparins, Doutremepuich, C. Low Molecular Weight Heparins in Clinical Practice, New York, Marcel Dekker, Inc, 1992, 23, 50
- Agnelli G. Pharmacological activities of heparin chains: should our past knowledge be revised? Haemostasis. 1996;26:2–9
- Montalescot G, Collet JP, Lison L. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol. 2000;36:110–114
[Abstract/Free Full Text] - Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. J Am Med Assoc. 1999;282:2058–2067
[Abstract/Free Full Text] - Lancet. 1999;354:701–707[CrossRef][Web of Science][Medline]
- Lancet. 1999;353:429–438[CrossRef][Web of Science][Medline]
- Kereiakes DJ, Grines C, Fry E. Combination enoxaparin and abciximab during percutaneous coronary intervention: a new standard of care? Curr Intervent Cardiol Rep. 2000;2:157–164[Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. M. A. LaPointe, A. Y. Chen, K. P. Alexander, M. T. Roe, C. V. Pollack Jr, B. L. Lytle, M. E. Ohman, B. W. Gibler, and E. D. Peterson Enoxaparin Dosing and Associated Risk of In-Hospital Bleeding and Death in Patients With Non ST-Segment Elevation Acute Coronary Syndromes Arch Intern Med, July 23, 2007; 167(14): 1539 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Part 8: Stabilization of the Patient With Acute Coronary Syndromes Circulation, December 13, 2005; 112(24_suppl): IV-89 - IV-110. [Full Text] [PDF]
|
|
|
|
|
|
Part 5: Acute Coronary Syndromes Circulation, November 29, 2005; 112(22_suppl): III-55 - III-72. [Full Text] [PDF]
|
|
|
|
 |
|
 K. W. Mahaffey, M. Cohen, J. Garg, E. Antman, N. S. Kleiman, S. G. Goodman, L. G. Berdan, C. J. Reist, A. Langer, H. D. White, et al. High-Risk Patients With Acute Coronary Syndromes Treated With Low-Molecular-Weight or Unfractionated Heparin: Outcomes at 6 Months and 1 Year in the SYNERGY Trial JAMA, November 23, 2005; 294(20): 2594 - 2600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Collet, G. Montalescot, G. Agnelli, F. Van de Werf, E. P. Gurfinkel, J. Lopez-Sendon, C. V. Laufenberg, M. Klutman, N. Gowda, D. Gulba, et al. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events Eur. Heart J., November 1, 2005; 26(21): 2285 - 2293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. de Araujo Goncalves, J. Ferreira, C. Aguiar, and R. Seabra-Gomes TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS Eur. Heart J., May 1, 2005; 26(9): 865 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al. Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur. Heart J., April 2, 2005; 26(8): 804 - 847. [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Harrington, R. C. Becker, M. Ezekowitz, T. W. Meade, C. M. O'Connor, D. A. Vorchheimer, and G. H. Guyatt Antithrombotic Therapy for Coronary Artery Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 513S - 548S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Wong, R. P. Giugliano, and E. M. Antman Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention JAMA, January 15, 2003; 289(3): 331 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Shinjo, I. L. S. Tersariol, V. Oliveira, C. R. Nakaie, M. E. M. Oshiro, A. T. Ferreira, I. A. Santos, C. P. Dietrich, and H. B. Nader Heparin and Heparan Sulfate Disaccharides Bind to the Exchanger Inhibitor Peptide Region of Na+/Ca2+ Exchanger and Reduce the Cytosolic Calcium of Smooth Muscle Cell Lines. REQUIREMENT OF C4-C5 UNSATURATION AND 1 right-arrow 4 GLYCOSIDIC LINKAGE FOR ACTIVITY J. Biol. Chem., December 6, 2002; 277(50): 48227 - 48233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Bertrand, M. L. Simoons, K. A.A. Fox, L. C. Wallentin, C. W. Hamm, E. McFadden, P. J. De Feyter, G. Specchia, and W. Ruzyllo Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Eur. Heart J., December 1, 2002; 23(23): 1809 - 1840. [Full Text] [PDF]
|
|
|
|
 |
|
 Enoxaparin Benefit in Unstable Angina Persists at 1 Year Journal Watch Emergency Medicine, April 17, 2002; 2002(417): 2 - 2. [Full Text]
|
|
|
|
|
|
J.J. Ferguson Moving beyond unfractionated heparin for acute coronary syndromes: Xeno's Paradox revisited Eur. Heart J., February 2, 2002; 23(4): 264 - 268. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||